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Abstract
Transmissible spongiform encephalopathies are believed to be caused by an infectious form of the prion protein,
designated PrPSc. The concentration of PrPSc is often poorly correlated to the level of infectivity. Infectivity can be measured
in two ways, namely endpoint titration and the incubation time assay, but patterns of infectivity vary depending on which
method is used. These discrepancies can be explained by variation in the aggregation state of PrPSc. Both methods of
measuring infectivity are modelled mathematically, and the theoretical results are in agreement with published data. It was
found to be theoretically impossible to characterise prion infectivity by a multiple of a single quantity representing ‘one
prion’, no matter how it is measured. Infectivity is instead characterised by both the number and sizes of the PrPSc
aggregates. Apparent discrepancies arise when these complexities are reduced to a single number. ß 2001 Elsevier Science
B.V. All rights reserved.
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1. Introduction
It has been hypothesised that the infectious agent
in transmissible spongiform encephalopathies may be
an abnormal form of the prion protein (PrP), desig-
nated PrPSc [1]. This protein-only or ‘prion’ hypoth-
esis has been extremely controversial, although it has
now become widely accepted. There is often a poor
correlation between the concentration of PrPSc pro-
tein and the corresponding number of infectious
units [2^5]. This puzzling ¢nding has sometimes
been used as evidence against the prion hypothesis
[4,6^9].
Theoretical kinetic work has shown that the prion
infectious agent must consist, at minimum, of a
PrPSc dimer or higher order oligomer [10]. In agree-
ment with this, target analysis has shown experimen-
tally that the minimum size of the infectious agent is
a PrPSc trimer or tetramer [11^14] or dimer [15]. All
prions are therefore aggregates of at least several
subunits, but PrPSc is seen in many heterogeneous
forms and is often much more substantially aggre-
gated. Discrepancies between the concentration of
PrPSc and the level of infectivity can be explained
by invoking variation in the extent of PrPSc aggrega-
tion. A large number of small aggregates is usually
assumed to have a di¡erent level of infectivity than a
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smaller number of larger aggregates [16]. Thus, for a
constant concentration of PrPSc, the measured level
of infectivity will depend on the extent of aggrega-
tion. The number of infectious units is not an abso-
lute physical quantity, related to the number of dis-
crete, uniform infectious particles, but is instead a
variable quantity that can be reversibly altered.
To understand the e¡ect of aggregation on infec-
tivity, and what infectivity really means in the prion
context, we need to understand how infectivity is
measured. The number of infectious units can be
measured in two di¡erent ways, known as endpoint
titration and the incubation time assay. For an end-
point titration, serial dilutions of a preparation are
inoculated into animals, and the dilution that will kill
half the animals is called an LD50 infectious unit [17^
19]. The number of LD50 infectious units in the orig-
inal preparation can be calculated from the dilution
factor.
Endpoint titration is time-consuming and requires
a large number of mice, so an alternative method,
known as the incubation time assay, was developed
[20]. The incubation time assay exploits the fact that
the incubation time in an animal is highly reprodu-
cible under certain conditions, and is inversely re-
lated to the size of the inoculating dose [21,22]. A
standard curve is generated for a given strain of mice
and a given route of infection, and is calibrated by
endpoint titration. The calibrated standard curve is
then used to calculate the number of infectious units
from the incubation time, and the results are usually
expressed in terms of LD50 units.
Unfortunately, these two methods are not always
equivalent [6,23^29]. It seems that the calibration
curve can shift under certain conditions. For exam-
ple, prion rods can be disaggregated into much
smaller detergent-lipid-protein complexes and lipo-
somes by sonication in the presence of detergents
[30]. This leads to a 100-fold increase in infectivity
as measured by endpoint titration [25], while it some-
times but not always leads to a mere 10-fold increase
in infectivity as measured by the incubation time
assay [30]. Similarly, sonication without the use of
detergents leads to a 17-fold increase in infectivity
as measured by endpoint titration [16], but no
change in infectivity as measured by the incubation
time assay [31].
Since the aggregation process may be complicated,
and is not well understood, there is currently no
straightforward de¢nition of what constitutes a sin-
gle prion particle. There is more than one physical
quantity that could reasonably be taken for ‘infectiv-
ity’. To explain discrepancies between the concentra-
tion of PrPSc, the level of infectivity measured by
endpoint titration, and the level of infectivity mea-
sured by the incubation time assay, we need to know
how measured infectivity depends on the size of the
aggregates. In other words, we need to know the
measured infectivity of a large number of small ag-
gregates relative to a smaller number of larger aggre-
gates. This is best done using a combination of the
experimental data mentioned above and mathemati-
cal modelling. On the mathematical side, a suitable
theoretical framework to describe prion replication
has already been developed [10,32^36]. In this frame-
work, aggregates take the form of macroscopically
linear polymers or oligomers, corresponding to ex-
perimentally observed prion rods and scrapie-associ-
ated ¢brils. Polymers or oligomers which contain
more than n PrP molecules grow by incorporating
new PrP monomers at the polymer ends, at a rate
which is independent of the polymer size. Larger
polymers eventually break into two smaller poly-
mers, completing the replication cycle. A range of
polymer sizes exists in any preparation.
In this paper, we explore what infectivity means
within the context of a mathematical model of prion
replication. We develop and use this mathematical
model to predict how the observed level of infectivity
should depend on the sizes of the prion polymers,
and relate these predictions to experimental data.
2. Materials, methods and results
2.1. Modelling the incubation time assay
Consider the kinetics of prion replication immedi-
ately after inoculation. We follow a kinetic model
presented elsewhere [36] and illustrated in Fig. 1.
Let y be the total number of infectious PrPSc poly-
mers of any size. The total number of PrPSc subunits
incorporated into infectious polymers is z. PrPSc
polymers are degraded at rate a, i.e., small polymers
are degraded at the same rate as large polymers. A
polymer of size i, i.e., containing i PrPSc subunits,
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breaks at rate b at each of the i31 joins along its
length. Oligomers below the critical size n can be
formed by breakage near a polymer end. These
oligomers are unstable and disintegrate rapidly into
monomers.
There is some controversy over which step is rate-
limiting for the incorporation of PrPC monomers
into polymers [34,37]. The alternative nucleated poly-
merisation and template-assistance hypotheses postu-
late di¡erent levels of dependence on the monomer
concentration. In the early stages of prion replica-
tion, however, the monomer concentration remains
constant, so these two hypotheses are indistinguish-
able. We can assume that monomers are incorpo-
rated into polymers at rate Py, where P depends in
some way on the monomer concentration. We then
obtain the following equations for the growth, deg-









These equations are linear, and can be solved ex-
plicitly. The amount of PrPSc as a function of time t
is given by
yt  c1r ae
rt  c2r2  aer2t
P 03bnn31 2a
zt  c1ert  c2er2t 2b
where













and c1 and c2 are constants speci¢ed by the initial
conditions. As t becomes large, the second terms in
Eqs. 2a and 2b become negligible. A variety of sim-
ulations were performed using realistic parameter
values [36] and a range of sizes in the initial inocu-
lum. In each case, a value of t much lower than the
incubation time was su⁄cient for the positive eigen-
value r to become dominant. After this point, the
number of polymers grows exponentially at the rate
given by the dominant eigenvalue r, in agreement
with experimental observations of exponential prion
growth [2,38,39]. The mean size of the polymers
reaches a steady state given by [36]
Fig. 1. Kinetic model of the early stages of prion replication, when monomer is not depleted. A polymer of length i is either degraded
at rate a, incorporates an additional monomer at rate P, or breaks at rate b at each of the i31 joins along its length. Breakage results
in two new polymers, one or both of which may fall apart if their size is smaller than n.
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and the progress of z is given by
zt  c1ert
The dependence of z on the initial conditions is
given by c1 rather than by z(0). This is a very im-
portant point, and constitutes the de¢nition of infec-
tivity measured by the incubation time assay. The
incubation time assay measures a quantity propor-
tional to c1, rather than to either the concentration
of PrPSc z(0) or the number of polymers y(0). The
logarithm of measured infectivity will be equal to log
c1 plus a constant. c1 can be calculated from Eqs. 2a
and 2b. Combining this result with Eq. 3 gives us
infectivityOc1  z0  y0s32n 1 s2s32n 1
4
We can see from Eq. 4 that c1, and hence the result
of the incubation time assay, depends both on z(0)
and on y(0).
2.2. Modelling endpoint titration
Consider a sample containing y prion polymers
which is diluted by a factor of 1/y, so that diluted
preparations contain on average one polymer. Not
all the diluted preparations will contain exactly one
prion polymer. Instead, some of the diluted prepara-
tions will not contain any prions, and thus will never
lead to infection, while other preparations will con-
tain more than one prion polymer. Assume for now
that the probability that a particular polymer is
present in a speci¢c dilution is independent of the
presence of other polymers in that dilution. Then
for a large number of polymers y in the initial prep-
aration, the number of polymers present in a speci¢c
dilution by factor d will follow a Poisson distribu-
tion, i.e., the probability that i polymers are present
is given by (yd)i/(i !eyd). A single polymer may initiate
infection with probability p, or it may be cleared with
probability 13p. Assume that each polymer in an
inoculum is independently capable of initiating infec-
tion. Then for an inoculum diluted by factor d from
a preparation originally containing y polymers, we
¢nd that






Note that the dilution factor d is not given here on
a log scale, as is normally the case. Since the sum of
a Poisson distribution is always equal to one, we
derive







This is the basic one-hit model [40], which has
been used to calculate prion infectivity [41]. The ba-
sic one-hit model predicts that the proportion of an-
imals infected as a function of the dilution factor
should have the form given by Eq. 5. This is a falsi-
¢able prediction that could be directly tested, given a
large enough set of experimental data. An alternative
hypothesis is that the one-hit model is not correct
because prions work co-operatively rather than inde-
pendently, and so prions can be ‘diluted out’ [41]. In
this case, a plot of ln(1-proportion of animals in-
fected) vs. the dilution factor would not give the
straight line through the origin predicted by Eq. 5,
and would instead curve to fall more steeply at high
doses.
Setting Eq. 5 equal to 0.5, we ¢nd that endpoint
titration gives
infectivityLD50units  pyln2 6
The number of LD50 units is therefore proportion-
al to the number of aggregates in a preparation. It is
not directly related to the size of the aggregates, but
may be indirectly related via the probability that a
single polymer will initiate infection p. If p is inde-
pendent of the polymer size, then Eqs. 5 and 6 are
valid as they stand. A more likely scenario is that the
probability of infection p(i) following inoculation by
a single polymer depends on the polymer length i. In
this case, the probability of infection resulting from a
polymer of length i is given by 13eydf ipi where f(i)
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is the frequency of polymers of length i. Overall, we
¢nd that









In other words, Eqs. 5 and 6 still hold, but now p





From Eq. 6, we know that the number of polymers
yP corresponding to one LD50 unit is equal to (ln2)/p.
The number of PrPSc molecules zP corresponding to
one LD50 unit, as measured by intracerebral inocu-
lation, has been estimated as 104^105 [42], 104 [43],
105 [1,44,45] and v105 [46]. If we know the mean size




For an inoculum consisting of prion rods, whose
mean size has been estimated as 1000 PrP molecules
[47], we take the consensus estimate of zP= 105, and
calculate that p = 0.007. Obviously, since s(0) and zP
cannot currently be measured very accurately, this
estimate of p is subject to substantial error.
We have assumed until now that the probability of
a polymer being present in a particular dilution is
independent of the presence of other polymers in
that dilution. This may not be true. Polymers might
clump together in the inoculum to form unstructured
aggregates of multiple macroscopically linear poly-
mers or prion rods. Our analysis is still valid if p is
taken to represent the weighted mean probability of
infection after inoculation with a single aggregate of
polymers, and s(0) is taken to represent the mean
sum of the polymer sizes within such an aggregate.
If polymers clump together, then the correct value of
s(0), and hence of p, will be substantially larger. Our
estimate of p = 0.007 should be taken as a lower limit
on p. The upper limit of p = 1 sets the upper limit for
the mean size s(0) of the aggregates of polymers to
zP/ln2W105, equivalent to 100 prion rods each con-
taining an average of 1000 PrPSc subunits. If this
upper limit is approached, then it is reasonable to
approximate p(i) as constant.
Alterations in the aggregation state may occur
during the dilution process itself, as polymers clump
together, are broken up and/or dissociation occurs
from the polymer ends. The speed with which the
dilution protocol is followed, and how long dilutions
stand on the bench before inoculation would then
a¡ect the results of endpoint titration. In agreement
with this, it has been found that signi¢cant losses of
infectivity measured by endpoint titration can occur
when inocula are left to stand for a period of 4 h in
glass bottles or syringes before injection [28].
Progressive dilution is likely to favour unclumping
of aggregates and to tip the balance of polymer
breakage and end-to-end polymer annealing in fa-
vour of breakage. Prion aggregates in more dilute
preparations may therefore have a smaller mean
size. In one study, the mean size of aggregates in a
dilute preparation was found to be around 1000 [48].
This could mean either that no clumping of rods
occurs so that the mean aggregate size is equal to
the mean rod size, or that both rod size and the
degree of clumping are low in a dilute preparation.
If the mean aggregate size progressively decreases
during successive dilutions, then the term yp in Eq.
5 will not stay constant for each dilution in an end-
point titration. A plot of ln(13proportion of animals
infected) vs. the dilution factor would then not be a
straight line, and would instead curve to fall less
steeply at high doses. This curve deviates from the
straight line predicted by Eq. 5 in the opposite way
to the case when prions act co-operatively and can be
‘diluted out’.
2.3. Comparison with data
In this section we use the mathematical models
presented above to explain data showing that soni-
cation leads to a greater increase in titre as measured
by endpoint titration than as measured by the incu-
bation time assay. Before sonication, prion rods con-
tain PrPSc in a fairly aggregated form of around 1000
PrPSc molecules per rod [47]. Clumps of these rods
are even more aggregated. After sonication, lipo-
somes contain only 2^4 PrPSc molecules on average
[30]. This ¢gure underestimates the mean size of the
prion polymers in the liposomes, since some lipo-
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somes may contain no functional prions. The small
size of the liposomes, however, ensures that the mean
size of prion polymers in liposomes is small.
Some PrPSc may irreversibly lose its infectious con-
formation during sonication. We assume for now
that this loss is negligible, and that z(0) therefore
stays ¢xed while the mean polymer size is reduced.
We also assume that the presence of liposomes has
no e¡ect on the speed or probability of infection
other than through the indirect e¡ect on polymer
size. It should be noted that this a very stringent
assumption, especially since the whole infection pro-
cess might well occur at the membrane. Nevertheless,
this assumption makes a suitable starting point for
the mathematical analysis, which can then be consid-
ered a limiting case. We can then derive from Eq. 4
the expression for infectivity measured by the incu-
bation time assay




where s(0) is the mean size of polymers in the inoc-
ulum, i.e., s(0) = z(0)/y(0) and s is the mean polymer
size at the site of replication in the host. This equa-
tion can be used to calculate the increase in infectiv-
ity when liposomes are formed, as measured by the
incubation time assay. This is shown in Fig. 2. In-
fectivity as measured by endpoint titration can be
calculated from Eq. 6 as
log infectivity  logp3logs0  constant 8
where in this case s(0) is equal to the mean size of
aggregates of polymers. The behaviour of this equa-
tion depends on how p varies with aggregate size.
There are two main factors that are likely to in£u-
ence this. The ¢rst factor is the intrinsic kinetics of
prion replication immediately after inoculation. The
model represented by Eq. 1 can be reformulated in a
stochastic form to describe this process. In this sto-
chastic model, the longer a polymer is, the more
likely it is to break into two viable polymers before
it is degraded. In addition, an aggregate of multiple
polymers may provide multiple opportunities for in-
fection. The probability of infection by a single ag-
gregate therefore increases in some way with size.
The second factor is that prions do not replicate
uniformly everywhere in the host. To successfully
initiate infection, a prion or its descendants must
be transported to a highly e¡ective site of replication.
This transport may occur by di¡usion, or it may be
more actively mediated. In either case, a small poly-
mer is more likely to be transported quickly, and is
therefore more likely to cause infection than a large
polymer.
It is not clear a priori what the balance between
these two factors will be, and so p may either in-
crease or decrease with polymer size. We consider
the simplest case ¢rst, namely that p does not vary
greatly, such that variation in log p is much less than
variation in log s(0). This case is illustrated in Fig. 2.
The rise in titre measured by endpoint titration de-
pends only on the size of the prion aggregates before
and after sonication into liposomes, and is therefore
independent of the host. In contrast, the extent of the
increase measured by the incubation time assay also
depends on the minimum polymer size n and the
mean polymer size s during prion replication at the
site of inoculation, and is therefore dependent on the
host animal, as shown in Fig. 2a. In practice, the
incubation time assay is fairly insensitive to the size
of the prion aggregates before sonication, unlike end-
point titration, as shown in Fig. 2b.
The calculated rise in titre is always larger as mea-
sured by endpoint titration than as measured by the
incubation time assay, in agreement with the data.
This makes intuitive sense. If p is constant, then two
small polymers of size m are twice as infectious as a
large polymer of size 2m in an endpoint titration.
During the incubation time assay, it takes some
time for the large polymer to break into two small
polymers, but less time than it would for a small
polymer to ¢rst grow and then break. The two small-
er polymers are therefore less than twice as infectious
as a single large polymer. Changes in size have less
e¡ect on the incubation time assay.
Now consider the case where the mean probability
p of infection by a single aggregate varies according
to the mean aggregate size. If p decreases with in-
creasing aggregate size, then the line would shift fur-
ther away from that of the incubation time assay.
This case is consistent with the data, but seems in-
tuitively unlikely. A large polymer may be less likely
to be transported, but it should readily break to form
multiple small polymers which will instead be trans-
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Fig. 2. The extent of the increase in titre is plotted against the size of the prion aggregates after sonication, according to Eqs. 7 and
8. The term p in Eq. 8 is constant. Prion rods are not clumped into aggregates of polymers. The endpoint titration assay shows a
larger rise in titre than the incubation time assay. (a) The initial size of the prion rods is taken as 1000 PrPSc subunits. The incubation
time assay shows a smaller rise in titre when the mean polymer size during in vivo replication s is small. (b) The initial size of the
prion rods makes little di¡erence to the incubation time assay, but substantially a¡ects the endpoint titration. In this graph, s = 100.
For both graphs, n = 2.
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ported. It is hard to imagine that the likelihood of
immediate transportation will dominate the likeli-
hood of breakage of a large polymer or dissociation
of an aggregate into its constituent polymers fol-
lowed by multiple opportunities for transportation.
If p increases with increasing polymer size, then
the line for endpoint titration in Fig. 2 would shift
closer to or past the line for the incubation time
assay. In the extreme case with p approximately pro-
portional to polymer size there would be no increase
in titre at all. We know from the experimental data
that titre does increase, and that the increase in titre
is always greater as measured by endpoint titration
than as measured by the incubation time assay, so we
know that the endpoint titration curve in Fig. 2 can-
not shift very far downwards. From the data, we can
therefore conclude that any increase in p must be
relatively small compared to an increase in the size
of the prion aggregates. Eq. 7 must vary less with
s(0) than Eq. 8.
Following disaggregation into liposomes, an in-
crease in titre is sometimes, but not always, seen
using the incubation time assay [30]. This can be
explained by the shape of the graphs in Fig. 2. The
incubation time assay shows very little increase in
titre when the size of the aggregates in the liposomes
is signi¢cantly greater than the mean polymer length
s during host replication. This small increase in titre
could easily be o¡set by the irreversible inactivation
of prions during sonication. When the prion aggre-
gates in the liposomes become very small, the titre
rises much more dramatically, and the increase may
therefore be noticed. If the degree of aggregation
changed slightly from one liposome preparation to
another within a critical region, substantial variation
in the incubation time could be seen. The location of
this critical region is speci¢ed by s, a parameter
which is at least partly determined by the host. We
therefore predict that di¡erent routes of inoculation,
di¡erent strains of mice and di¡erent levels of PrP
might all in£uence the location of this critical region.
In summary, our predictions are in qualitative
agreement with the experimental data. Quantitative
comparisons are limited by the small quantity of
data available relative to the number of parameters
in the models, and by the numerous simplifying as-
sumptions that have been made.
3. Discussion
Prions, as unconventional infectious agents, can-
not be characterised merely by a single number, no
matter how it is measured. The infectivity of a given
preparation should be speci¢ed by both the number
of prion polymers and their mean size, if not by the
entire polymer size distribution. It is possible to de-
¢ne a minimally infectious particle, which may be a
PrPSc dimer, trimer or tetramer, but prion prepara-
tions are not simple integer multiples of this mini-
mally infectious particle. It may not be correct to
think of a long prion rod as composed of discrete
minimally infectious particles. When a sample is sub-
jected to simple manipulation which changes the ag-
gregation state, the number of infectious units may
not stay constant when only a single measurement is
used. This poses a problem for both endpoint titra-
tion and the incubation time assay, and highlights
the need for improved techniques that can accurately
characterise amyloid sizes.
Endpoint titration is not always superior to the
incubation time assay. For example, a substantial
increase in titre measured by endpoint titration has
been noted following especially vigorous homogeni-
sation [49] or sonication [16]. Variation in the extent
of homogenisation could be a source of error in some
experiments, and could be minimised using the incu-
bation time assay. Likewise, variation in the dilution
protocol and the time before injection may also lead
to signi¢cant error in endpoint titration experiments
[28]. Understanding the basis of the di¡erences be-
tween the two assays can help decide when it is
worth the additional resources to perform an end-
point titration.
The comparison between the two assays can also
yield information. For example, inocula taken from
the spleen lead to a longer incubation period than
the same number of LD50 units taken from the brain
[22,27]. This may be because other components of
the tissues alter the probability or speed of infection.
Alternatively, it may be because the mean polymer
size in the spleen is smaller.
Similarly, the level of infectivity measured by the
incubation time assay rises faster than either the level
of PrPSc in enriched fractions [2] or the level of pro-
teinase K-resistant PrP [38] during the natural course
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of infection. This may be because samples taken
early in infection contain a higher ratio of other
brain material to infectivity. The high level of other
brain material may promote a greater non-speci¢c
response, causing infection to be cleared more e¡ec-
tively and therefore proceed more slowly in the test
animals. Infectivity present early in infection is there-
fore underestimated, and the rate of increase of the
infectivity is overestimated [36]. Alternatively, the
mean polymer size may be progressively reduced dur-
ing the natural course of infection, perhaps because
small polymers with high breakage rates tend to
grow faster than larger polymers, and therefore grad-
ually come to dominate [36]. Repeating this experi-
ment using endpoint titration would yield additional
information. According to the second hypothesis, in-
fectivity should rise still more rapidly when measured
by endpoint titration. This is not necessarily the case
under the ¢rst hypothesis. Hopefully, new biophysi-
cal techniques such as £uorescence correlation spec-
troscopy will be able to directly test the role of ag-
gregate sizes in such phenomena.
We have described one reason why endpoint titra-
tion and the incubation time assay might give diver-
gent results. It is also possible that chemical and/or
heat treatments might modify the infectious agent in
some way other than the extent of aggregation.
Modi¢ed prions or inorganic prion templates [50]
might be slower to initiate infection and may encoun-
ter something analogous to a species barrier. This
can explain why many inactivation experiments
show that titre is reduced more as measured by in-
cubation time assay than as measured by endpoint
titration [6,23,26,29]. It is also possible that smaller
prions are more likely to survive the inactivation
procedures than larger polymers, providing an alter-
native explanation for this data. The two explana-
tions for the di¡erences between the assays are not
mutually exclusive, and each may be more or less
relevant to speci¢c experiments.
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